George B. Abercrombie - Feb 15, 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Director
Signature
/s/ Alane P. Barnes, by power of attorney
Stock symbol
BCRX
Transactions as of
Feb 15, 2022
Transactions value $
-$75,900
Form type
4
Date filed
2/16/2022, 03:25 PM
Previous filing
Nov 17, 2021
Next filing
Apr 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Options Exercise $16.6K +5K $3.32 5K Feb 15, 2022 Direct F1
transaction BCRX Common Stock Sale -$92.5K -5K -100% $18.50 0 Feb 15, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Automatic Stock Option Grant Options Exercise $0 -5K -50% $0.00 5K Feb 15, 2022 Common Stock 5K $3.32 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021.
F2 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $18.00 to $18.76. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F3 The option vested 1/12 per month for a period of 12 months, beginning on June 23, 2012.